促销!

Cagri + Sema

原价为:$195.00。当前价格为:$185.00。

+ Free Shipping
SKU: N/A 分类:

Cagri + Sema (Cagrisema, Cagrilintide + Semaglutide Blend)

⚠️ Disclaimer: For Research Use Only. Not for human administration or clinical therapy.

Cagri+Sema = Cagrilintide + Semaglutide, commonly named Cagrisema, multi-receptor agonist peptide blend. Two separate peptides mixed as lyophilized powder, not a single fused molecule.

Individual Components Specs

1. Semaglutide

  • CAS: 910463-68-2
  • Sequence: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEA-AEEA-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
  • MW: 4113.58 g/mol

2. Cagrilintide

  • CAS: 2415862-83-2
  • Sequence: Ac-[MeLeu¹⁰, His¹¹, Glu¹⁶, desPro³⁷]-amylin analog, 37 amino acid peptide, C-terminal amide
  • MW: 3990.46 g/mol

Blend Info

  • Appearance: White to off-white lyophilized powder
  • Typical research formulation ratio: Cagrilintide : Semaglutide = 1:1 molar / weight ratio (customizable)
  • Solubility: Soluble in weak acidic aqueous buffer
  • Storage: Lyophilized powder stored at -20℃, protected from light and moisture. Avoid repeated freeze-thaw cycles. After reconstitution, refrigerate and use promptly.

Development Background

Cagrisema combines two distinct peptide agonists:

  1. Semaglutide: GLP-1 receptor agonist, long-acting, DPP4 resistant.
  2. Cagrilintide: Amylin receptor agonist (calcitonin receptor/RAMP complex). The combination is studied for synergistic metabolic effects, originally from Novo Nordisk clinical research programs.

Mechanism of Action (Research Findings)

  • Semaglutide (GLP-1 agonist): Glucose-dependent insulin release, suppress glucagon, slow gastric emptying, reduce appetite via hypothalamic GLP-1R.
  • Cagrilintide (Amylin agonist): Further slows gastric emptying, inhibits postprandial glucagon, enhances satiety.
  • Synergy: Dual receptor activation produces stronger reduction in food intake and body weight compared to single agent in preclinical metabolic models.
  • Combined modulation of glucose homeostasis, energy expenditure and appetite signaling.

Research Areas

  • Obesity & weight loss animal models
  • Type 2 diabetes, glycemic control
  • GLP‑1 / amylin receptor dual signaling
  • Appetite, satiety and food intake research
  • Pharmacodynamic synergy of peptide co-administration
Specifications

5mg+5mg

评价

目前还没有评价

成为第一个“Cagri + Sema” 的评价者

您的邮箱地址不会被公开。 必填项已用 * 标注